Cvijic Christine Mikail 4

What Happened

• Christine Cvijic, President and Chief Financial Officer of Neurogene, reported the sale of 2,558 shares on March 26, 2026. The shares were sold at a weighted-average price of $21.62 for total proceeds of $55,316. This transaction was a sale performed to satisfy tax withholding obligations arising from partial vesting of a restricted stock unit (RSU) award, not an independent open-market investment decision.

Key Details

• Transaction type: Sale (S); transaction date: 2026-03-26; filing date: 2026-03-30 (timely within the Form 4 two-business-day window).
• Price: weighted average $21.62; individual sale prices ranged from $21.10 to $21.91. Reporting person can provide per-price breakdown on request (footnote F2).
• Reason: Mandatory share sale to cover tax withholding on RSU vesting (footnote F1). The award agreement requires the company to sell sufficient shares to cover the withholding; the reporting person did not make an election to retain shares.
• Holdings/awards noted (footnote F3): remaining unvested RSUs include 10,635 (granted 3/13/2024, vest 3/13/2027), 13,533 (granted 3/26/2025, vesting in equal installments 3/26/2027 & 3/26/2028), and 22,000 (granted 2/20/2026, vesting in equal installments 2/20/2027–2/20/2029). Additionally, 19,200 shares are held jointly with spouse David Cvijic.
• Filing timeliness: Filed March 30, 2026 for a March 26 transaction — appears timely under Section 16 rules.

Context

• This sale was a mandatory, tax-withholding sale tied to RSU vesting (routine administrative sale), which is different from a discretionary insider sale that might signal a change in sentiment. Retail investors typically view mandated withholding sales as neutral rather than a negative signal about company prospects.